secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2023-12-01T23:59:59+00:00
Accession:  0001193125-23-286862
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke presents STK-001 data at AES 2023: seizure reductions and cognition gains in Dravet syndrome
--------------------------------------------------------------------------------

- Higher STK-001 brain exposure linked to greater seizure reductions in 72 patients (R=-0.23, P<0.001).
- Multiple 70mg doses of STK-001 showed the largest reductions in convulsive seizure frequency.
- 90% of Phase 1/2a completers enrolled in open-label extension studies (SWALLOWTAIL & LONGWING).
- BUTTERFLY natural history study: patients on ~3.5 anti-seizure drugs saw no meaningful seizure improvement over 2 years.
- OLE data showed substantial improvements in cognition and behavior over 12 months, supporting disease modification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000119312523286862/0001193125-23-286862-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000119312523286862/d619524d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-286862

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer